Company profile: Valerio Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
Products and services
- AsiDNA™: A DNA-decoy molecule that mimics double-strand breaks in tumor cell DNA, preventing repair and inducing cancer cell death
- PlatON™ Platform: A proprietary chemistry platform that engineers compounds targeting intracellular DNA-binding proteins via a decoy mechanism to develop treatments for tumors and inflammatory diseases
- VIO-01: A next-generation DNA decoy engineered to disrupt multiple DNA repair pathways and activate antitumor immune responses via the STING pathway
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Valerio Therapeutics
Miroculus
HQ: United States
Website
- Description: Provider of hands-off sample-to-answer solutions for molecular testing, delivering assay flexibility and automation via an affordable digital microfluidics platform that enables seamless workflow integration from novel molecular protocols to data analytics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Miroculus company profile →
Nuvation Bio
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical therapies addressing unmet needs, developing oral targeted candidates including Taletrectinib (CNS-active, selective next-generation ROS1 inhibitor for ROS1-positive NSCLC), Safusidenib (potent mIDH1 inhibitor for grades 2-3 IDH1-mutant glioma), NUV-868 (BD2-selective BET inhibitor targeting BRD4), and NUV-1511 (drug-drug conjugate candidate).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvation Bio company profile →
Avidea Technologies
HQ: United States
Website
- Description: Provider of polymer-based drugs delivering nanoparticle vaccines for cancer treatment and infectious diseases, using uniform-size nanoparticles designed to target specific tissues and cell populations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avidea Technologies company profile →
Lumicell
HQ: United States
Website
- Description: Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumicell company profile →
Endomag
HQ: United Kingdom
Website
- Description: Provider of magnetic sensing technologies for breast cancer care, including the Sentimag surgical guidance system to detect tumors and lymph nodes, Magseed markers for precise tissue and lymph node localization, Magtrace lymphatic tracer for sentinel node biopsy with clear signal and visual guidance, and Magseed Pro self-expanding seed for precise deployment and anchoring.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endomag company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Valerio Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Valerio Therapeutics
2.2 - Growth funds investing in similar companies to Valerio Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Valerio Therapeutics
4.2 - Public trading comparable groups for Valerio Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →